H.C. Wainwright analyst Sean Lee lowered the firm’s price target on Casi Pharmaceuticals (CASI) to $4 from $6 and keeps a Buy rating on the shares. The firm expects the divestment of the company’s Chinese business to occur before the end of Q3.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals: Strategic Divestment and CID-103 Potential Drive Buy Rating
- CASI Pharmaceuticals Acquires Precision Autoimmune Therapeutics
- CASI Pharmaceuticals Receives Updated Acquisition Proposal for China Operations
- CASI Pharmaceuticals receives proposal to acquire China business for $20M
- CASI Pharmaceuticals Reports 2024 Financial Results and Strategic Developments
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue